Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
In the D-Gal + FOXO4-DRI group, mice also received D-galactose injections and, after 4 weeks, were given intraperitoneal injections of FOXO4-DRI (5 mg/kg, MCE, HY-P4157) every 2 days for 4 weeks, followed by tissue collection
IGF-1 LR3: not FDA-approved and chemically distinct from the FDA-approved pediatric drug Increlex
Request More Information Prescribers
Moron MS et al
**AOD 9604 in Bodybuilding: Building Lean Mass** Bodybuilders often seek ways to reduce body fat while preserving lean muscle mass
The administration of BPC-157 resulted in a marked reduction of these lesions, suggesting its protective role against NSAID-induced organ damage
